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CHAPTER I
INTRODUCTION
Through the ages man has tried to conquer disease with his scientific
knowledge and ability.

In the treatment of neoplastic diseases many

chemotherapeutic agents have been introduced which have resulted in varying
degrees of success.
has

One such group of agents, the folic acid antagonists,

been utilized for the past twenty years in cancer chemotherapy.

Today, methotrexate is the most widely used member of this group of agents •

.

However, as is the case with most anti-neoplastic drugs, the concomitant
side effects that occur with therapeutic doses have limited its optimum
utilization.
The complaint of a sore, painful mouth with a hyperemic appearance is
a well-known side effect from methotrexate therapy.

Many hematologists

use the oral mucosa as a general indicator of the therapeutic effectiveness
of this drug.

Once the stomatitis has appeared, the drug is discontinued,

and it is assumed that the optimal drug effect has been attained.

Of

course, regular hematologic studies and analyses are performed in conjunction
with the therapy.
Although the modern medical literature contains many case reports
and experimental investigations concerning the activity of methotrexate,
very little is to be found regarding the specific dynamic effect on the
1

2
oral epithelium.

In ordei to study this effect, the autoradiographic

technique has been employed in this study.

This technique has previously

been utilized to measure the turnover rate of various other tissues throughout the body, but has never been used on the oral epithelium for this
purpose.

CHAPTER II
REVIEW OF THE LITERATURE
A.

Methotrexate

Physical Properties
The chemical processes of life occur continuously in all living organisms with the aid of special proteins, the enzymes.

These react with

food substances and with small molecules arising from these substances,
which are termed metabolites.

Huennekens and Osborn (1959) stated that

coenzymes, including certain vitamins as folic acid, are metabolites which

.

are present in only very small amounts in living tissues, but are essential
for normal and continued function of the tissues.

Stokstad (1954) men-

tioned that deficiency states of folic acid were described in man, monkeys,
chicks, rats, guinea pigs, insects and microorganisms long before the
vitamin was isolated and characterized.
Willis, et al, (1931) in Bombay attempted to identify a factor in
yeast autolysate and crude liver extract which prevented some forms of
megaloblastic anemia.

Pfiffner, et al, (1934, 1944) were the first to

isolate folic acid, or more exactly, pteroylglutamic acid (PGA).

(Fig. la)

Angier, Subbarow (1946) and their group at Lederle Laboratories found
that a growth factor for Lactobacillus casei was similar, if not identical,
to the factor above.

They were able to determine its constitution and

were the first to synthesize it.

3
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Bessey (1953) stated that the vitamin folic acid has been shown to be
essential in cells for their normal growth, maintenance, and functioning
of their cellular processes.

These reactions can be blocked by certain

chemicals which displace metabolites from enzymic reactions, thereby interfering with biochemical processes.
Delmonte and Jukes (1962) noted that the folic acid antagonists owe
their profound biological activities to their ability to compete with the
vitamin folic acid.

These metab9lic antagonists, such as methotrexate and

aminopterin, are very similar in molecular structure to folic acid, except
for the presence of additional chemical group(s).
Seeger, et al (1947) were the first to synthesize certain derivatives
of folic acid, namely aminoproterin and amethopterin.

The brand name of

amethopterin is methotrexate.
In aminopterin the folic acid hydroxyl group in the 4-position of the
pteridine ring is replaced by an amino group, thereby giving this folic
acid antagonist its potency.
. teroylglutamic acid.

The chemical name for aminopterin is 4-aminop-

(Fig. lb).

Methotrexate has in addition a methyl

group on the amino nitrogen between the pteroyl and benzoyl group and is
named 4-amino-N

10

-methylpteroylglutamic acid.

(Fig. le)

Rall (1963) described methotrexate as a moderately large molecule
with a molecular weight of 454.4.

It is fairly soluble as the salt in

aqueous solution, but is insoluble in lipoid solvents at body pH.

The two

carboxyl groups in the glutamic acid portion of the molecule render it a
fairly strong acid.

Furthermore, the amino group (NH ) on the pteridine
2
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ring can ionize to a limited extent as a weak base.
cription resembles that of penicillin.

In general, this des-

Therefore, he concluded that after

methotrexate ingestion there would be a limited degree of oral absorption,
a volume of distribution largely confined to the extracellular spaces, and
a limited penetration into the cerebralspinal fluid and brain.
The molecular chemistry of the pteridines is complex and the separation of related compounds has been very difficult.

Oliver

(1961) was only

able to attain an eighty-five per cent degree of purity of methotrexate.
Distribution and Fate of Methotrexate
In order to understand the action of methotrexate in the body, one
must first strictly define its tisstle distribution.

Methotrexate has been

observed to persist in human liver, kidney and spleen.

These tissues have

been attributed by Dietrich et al (1952) to normally have a high folic acid
and citrovorum factor.
Timmis (1967) stated that when folic acid is reduced and formylated,
and the product is treated with alkali, 5-formyltetrah.ydrofolic acid is
produced.

It is also known as folinic acid leucovorum or citrovorum

factor and is used as the most effective antidote against methotrexate
toxicity.
Cherache (1960) and Freeman (1958) both concluded that the duration
and amount of drug persistence are independent of the dosage, route of
administration and duration of drug therapy.
Condit (1957, 1960) with human subjects, and Rall (1959) with rats
and dogs showed that better absorption and maintenance of drug blood levels

•
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were obtained with repeated small doses rather than with single large
doses.

However, drug toxicity also increases when this method of intake is

utilized.

.

Berlin(l963) suggested that some of the drug does penetrate cells
since the folic reductase system is intracellular.
Fountain et al (1953) used bioautographs to show that high

concentra-

tions of methotrexate persist in the tissues of the normal mouse (20 grams)
for a period of three weeks and, in one instance, as long as eight months
in the liver.

A decrease in kidney concentration of methotrexate was also

noted within 24 hours.

The mouse rapidly eliminated all the methotrexate

in excess of its renal threshold.

He assumed that the methotrexate which

was retained for such long periods of time was incorporated up to a relatively constant concentration in enzymes ordinarily associated with folic
acid and citrovorum factor and any excess was rapidly excreted.
More recently, Henderson and Oliverio (1965) studied several different
groups of male mice with various dosages of tritiated methotrexate.

In the

first group, 15 mg/kg was given and they observed that after twenty-four
hours, most of it had been excreted with the remainder being distributed
throughout the body tissues.

Only the liver, kidney, stomach and gonads

consistently contained greater quantities of radioactivity than did the
remaining organs of comparable size.

The bulk of the drug was excreted in

the urine, and about 15 per cent appeared in the feces, apparently derived
from biliary excretion.

The urinary excretion was over 50 per cent in

four hours after injection and 60 - 80 per cent by eight hours.

At the end

of the twenty-four (24) hour period, almost all of the original dose was

7
recovered.

This confirmed the earlier findings of Werkheiser (1963) who sta-

ted that methotrexate was excreted fairly rapidly through renal pathways
also that some biliary excretion occurred.

The second group was pre-

treated for five days with 0.5 mg/kg/day of unlabeled methotrexate.

This

did not significantly alter the pattern of excretion, although total recovery
of the drug was slightly reduced.

A third group was administered 0.5 mg/kg

of tritiated methotrexate for six consecutive days.

However, this too

failed to change the total amount of retained radioactivity or the proportions in the fractions obtained.

The relatively constant proportions in

the counts in each fraction of liver tissue appeared to reflect the dynamic
equilibrium between subcellular components rather than binding sites with
either sequential or variable priority for the drug.

The majority of the

remaining labeled methotrexate was precipitated with the nucleus and stromal
elements during the 600 times "g" centrifugation.
The distribution in the liver was similar to that reported by Werkheiser (1961) and is consistent with his proposal that methotrexate binds
to the enzyme folic reductase which resides in the soluble fraction of
1i ver cells.

Since the antagonists are essentially irreversibly bound to folic
reductase, Werkheiser (1962) suggested that the drug remains in the cell
until the cell's death and removal from the body; and that the half-times
represent an estimate of the turnover of the two populations of cells in
the liver, and of the turnover in the intestinal mucosal cells.

8
Henderson et al (1965) established that about fifty per cent of methotrexate in mouse plasma was reversibly bound to proteins.

The majority

of this binding was associated with the albumin fraction, but its stability
has not been determined.

However, they felt that the degree of this binding

was relatively constant over a remarkably wide range of concentration.
Johns (1961) found a similar degree of protein binding with tritiated
folic acid.

Johns et al (1964) performed in vivo studies indirectly com-

paring the affinity of a variety of folic analogs for folic reductase, and
this resulted in the following ranking as far as their ability to displace
bound tritiated methotrexate:
formyl tetrahydrofolic acid

methotrexate

dihydrofolic acid

folic acid

methyl.tetrahydrofolic acid.

Fischer (1962) and Wood et al (1961) have demonstrated a possible
active transport mehcanism for methotrexate absorption.
In a recent experiment, Condit and Yoshino (1968) studied the displacement of 0.1 mg/kg of tritiated methotrexate by three compounds.

They

observed that after injection of tritiatiated methotrexate, the total
radioactivity in the small intestine disappeared more rapidly than from the
liver and kidney.

Displacement of tritiated methotrexate from these three

tissues increased following increasing doses of unlabeled methotrexate
until almost all of the radioactivity in the organs was displaced by 10 mg/kg
of unlabeled methotrexate.

A dose of 25 mg/kg of folic acid displaced 25

per cent of tritiated methotrexate from the liver, but the same amount of
citrovorum factor failed to displace any isotope.

9

Their chromatographic studies of the intestine revealed almost all
the radiation tritiated methotrexate remained unchanged.

The liver homo-

genate yielded a large peak of bound-form isotope, a relatively small
.peak of free tritiated methotrexate, and a very small peak of an unknown
metabolite.
There is no evidence that methotrexate is metabolized in any mammals.
Whatever amount is not bound by the folic reductase is excreted unchanged.
Mechanism of Action
Biochemical Alterations
Friedkin (1963) noted that the enzyme folic reductase, or as it is
also known,

dihydrofolic reductase; specifically catalyzed the reduction

of folic acid to tetrahydrofolic acid and that in folic acid biosynthesis
the dihydro form was the final product.

Brown, Weisman and Molmar (1961)

established that dihydrofolic acid was the initial compound required for
the biosynthesis of tetrahydrofolic acid and its derivatives.
Tetrahydrofolic acid (FAH4 ) is involved in the transfer of single
carbon units in biochemical

rea~tions

involving the de

~

synthesis of

purines and pyrimidines, such as thymine, methionine, and serine, which
eventually lead to the synthesis of nucleic acids.
Demonte and Jukes (1962) stated that mehtotrexate's usefulness is
primarily due to the firm combination with

th~

folic reductase system,

thereby interferEi,ing with these biosynthetic pathways among which is the
synthesis of thymidylic acid which leads to DNA.

(fig. 2).

Methotrexate

is not reduced by the folic reductase system and once it has combined with
the enzyme, the antagonist takes no further part in the biochemistry of cells
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Mead (1963) felt that folic reductase was inhibited by a number of
folic acid analogs.

Through this inhibition, methotrexate and the other

analogs could cause a depletion of various coenzyme

forms, thereby reduc-

ing activity in the biosynthetic pathways which utilize them.
Mead also stated that the de

~

biosynthesis of purines started

with ribose-5-Po , and constructed the purine nucleus, step by step, to
4
form the purine nucleotide inosinic acid.

Two tetrahydrofolate enzymes are

involved in this sequence, each contributing a one-carbon unit at the
oxidation level of formate to the final purine nucleus.

In this instance,

methotrexate interfered with this biosynthetic pathway by inhibiting the
folic reductase which supplies the two tetrahydrofolate enzymes.
Another key biochemical pathway known to be inhibited by folic acid
antagonists is the biosynthesis of thymidylic acid which is essential for
the synthesis of desoxyribonucleic acid (DNA).

Here the enzyme thymidylate

synthetase was found by Wahba and Friedkin (1961) to transfer a one-carbon
unit from mehtylenetetrahydrofolate (from folic acid activation) to
deoxyuridylic acid.
dihydrofolic acid.

The products of the reaction are thymidylic acid and
(Fig. 3).

McDougall and Blakeley (1961) proposed that methotrexate, as is true
of all folic acid antagonists, exerted an indirect inhibitory effect on
this reaction by blocking dihydrofolate reductase.
~cid

That is, since the folic

cycle is dependent upon the regeneration of tetrahydrofolate from

dihydrofolate, the inhibition of the reductase prevented further formation
of methylenetetrahydrofolate and the overall effect was an inhibition of

11
thymidylate synthetase.

(Fig. 3).

This is in contrast to the direct in-

hibition of thymidylate·synthetase by the fluorinated pyrimidines, which
has been established by Hartmann and

Heidelberger (1961).

A similar indirect inhibition by methotrexate occurs in the synthesis
of methionine as reported by Larrabee (1961).
Thus many of the effects of methotrexate can be explained by the inhibition of folic acid reduction, both with respect to its highly spcific
tissue toxicity and to its pharmacologic effects.
Werkheiser (1961) illustrated the affinity of methotrexate for the
enzyme folic reductase by the fact that nearly eighty per cent of its
activity remained in the supernatant•after sucrose fractionation of treated
rat liver.

He also showed that the affinity of the partially purified

folic reductase for methotrexate was about 100,000 times greater than for
folic acid at pH 6.0 and 20,000 times as great for dihydrofolic acid at
pH 7.5.

Therefore, the enzyme was quickly saturated by the inhibitor, lead-

ing to pseudoirreversibility and the exclusion of folic acid from the
enzyme.

This strength of association between the drug and the enzyme was

so great that the drug acted as a titrating agent.
Werkheiser (1961) used the term "stoichiometric" to describe this inhibition, since the amount of methotrexate bound by the soluble supernatant
proteins of the rat liver was claimed to be precisely the amount required
to inhibit the folic reductase in the preparation.
tion of enzyme with drug.

This allowed a titra-

Removal of the drug from the protein by dialysis

against folic acid resulted in precisely equivalent reactivation of the
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enzyme.

He concluded that folic reductase was the agent in rat liver which

binded the 4-arnino derivatives of folic acid, both in vivo and in vitro,
and thus probably represented the mechanism of long term retention of
these drugs in the animal.
Using this procedure he showed that about half of the methotrexate
which was retained in mouse liver twenty-four (24) hours after a single
injection was lost very slowly. He arrived at a half-time of over ninety
days.

This work confirmed the findings of Fountain (1953) and Cherache

et al (1960). Werkheiser felt that this stoichiometric relationship indicated that methotrexate was a very potent inhibitor of folic reductase
and that within twenty-four (24) hours no free drug was available to inhibit any other enzyme.
Timmis (1967) stated that subsequent work on the drug-enzyme relationship and their interaction indicated that the binding of the drug to
protein was more than could be accounted for by the amount of folic reductase present.

This suggested that binding to non-specific protein may be

a prerequisite of the metabolism of folic acid and its antagonists.
Condit (1961) suggested that the activity of methotrexate was mediated
by some additional mechanism.

In 1965 he confirmed that the antifolics had

important sites of action in addition to inhibiting folic reductase.

He

noted the blockage of folic reductase in mouse liver by aminopterin and
methotrexate with in vivo doses of 0.1 mg/kg.
Werkheiser (1963) elaborated on the ever present reality of auxillary
problems which are associated with methotrexate therapy and its success
and failure.

These included the drug's side effects on the host, chemical

••
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modifications of the drug to make more effective agents, special excretorjr mechanisms, limitations of access of the drug to its site of action
due to permeability or active transport restrictions, intracellular compartmentation of the drug, and rate of recove:rry- from the drug's effect.
These problems are recognized, but as yet unsolved, and he felt that
they should be considered when evaluating the therapeutic efficacy and
the success of methotrexate treatment.
In addition to the above, the

in.~ibition

of f olic reductase by

methotrexate has also been well documented by Osborn et al (1958),
Peters (1958), and Zakrzewski (1960).
To understand the exact intracellular action of methotrexate, it
is convenient to observe the course of events following a single dose of
methotrexate as described by Werkheiser (1963).

The drug enters the

cell rather rapidly, perhaps in amounts in excess of that needed to abolish folic reductase activity.

The resulting effect is a profound in-

hibition of thymine synthesis with a lesser but still very strong inhibition of purine _ synthesis.
Thiersch, et al (1949) found by microscopic observation that protein synthesis continued during a period of obvious methotrexate toxicity;
yet the cells were inhibited by the drug.
plasmic volume microscopically.

He observed increased cyto-

Van Scott (1959) noted enlarged epithe-

lial tonofibrils in the epithelialization of psoriatic patients treated
with methotrexate.

These observations led Werkheiser (1963) to deduce

that there was a continuation of protein synthesis during a period of

14
obvious methotrexate toxicity.

Therefore, he concluded that the presence

of the drug in a cell causes an abrupt cessation of multiplication, but
permits a moderate synthesis of proteins, including that of folic reductase.

Hakala (1962) showed that this enzyme could be synthesized at a

significant rate by the fact that the inhibitory level of methotrexate
for resistant S-180 cells in culture was determined by the balance between
the rate of drug entry and the rate of enzyme synthesis.

Hence, if the

supply of this critical enzyme has been replenished, the cells recover
and

resu~e

mitosis.

The free drug in the cell now has two alternate pathways open to
it.

Fischer (1962) found that part of it will pass out of the cell at a

relative1y slow rate, while part of it will conibine with newly formed
enzyme.

When enough free enzyme is present, normal division processes

would resume provided that the activity of folic reductase had not been
abolished for twenty-four hours or more.

Such cells would suffer irre-

versible damage.
Werkheiser (1962; et al 1963) found that a particular dose of the
drug,which was high enough to inactivate al.l the enzyme that could be
found during the critical period, was so closely related with the toxicity
and the tumor sensitivity.

He also determined that the dose necessary to

reduce the free enzyme level of the intestinal mucosa to negligible levels
was almost precisely the LD

50

•

Fisher (1962) and Werkheiser (1962) both proposed that the primary
parameter for defining the sensitivity of a tissue to methotrexate would
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be the rate of entry of the drug into that tissue.
that other phenomen;i.

Therefore, they felt

besides the level of the enzyme in the tissue were

responsible for the effect of this drug on different tissues.
As long as free drug exists, activity of folic reductase would be
abolished.

During this time no tetrabydrofolate could be formed from

dibydrofolate.

For non-dividing tissues such as liver and kidney, this

would be of little consequence, since these tissues have large stores of
tetrabydrofolate compounds.

However, rapidly dividing tissues, for exam-

ple, intestinal mucosa, bone marrow, oral mucosa, and tumors, contain
much smaller amounts of tetrabydrofolate compounds (Nichol, 1953), but
continue to oxidize them to dibydrofolate in the process of thyrnidylate
synthesis.

Therefore, Werkheiser (1963) explained that these tissues

could become depleted of their stores of reduced folate cofactors quite
readily, despite the normal circulating blood level of these compounds,
which apparently is too low.

If this situation were maintained, they

would undergo "thyrnineless death" as Cohen (1956) has described.
Both Werkheiser (1961) and Williams (1955) established that the
synthesis of thyrnidylate appeared to be more sensitive to the action of
methotrexate than were the other reactions requiring tetrabydrof olate.
Since Werkheiser et al (1963) showed that the rate of methotrexate
entering cells differs from one tissue to another, a dose adequate to
provide free intracellular methotrexate for a considerable period in
one tissue, ma,y not suffice even to saturate all of the folic reductase
in another tissue.

Burchenal et al (1961) investigated the effect of the administration of the final amino acid end products of the f olic reductase system
reactions on the toxicity of methotrexate therapy.

They noted that Skipper

was unable to prevent the inhibiting anti-leukemic effects of methotrexate by the administration of tbymidine (TDR), adenine, histidine, methionine and serine either alone or in combination when they were given on a
three times weekly dosage schedule.

Burchenal used various dosages of

methotrexate in order to find out which of the metabolic pathways interrupted by the drug was responsible for the toxicity.

He found that metho-

trexate on a 0.2 mg/kg per dose five times daily for ten days was lethal
to seventeen of twenty (20) mice.

Using this drug dosage schedule, 20

mg/kg per dose of tbymidine gave no protective effect.
of serine, methionine, and histidine at 10 mg/kg.

The same was true

However, adenine at

10 mg/kg gave complete protection against methotrexate at 0.2 mg/kg., but
not against 0.4 mg/kg of methotrexate.

The addition of tbymidine a.lone

at 20 mg/kg or of tbymidine plus the three amino acids gave no additional
protection.

They also stated that methotrexate in the mouse and man pro-

duced toxicity at significantly smaller dosages when given by frequent or
continuous infusion.
Grant (1958, 1960) using the Rana pipiens erribryo as the experimental system, revealed the effect of antifolic compounds on both DNA and
RNA.

The regions showing the highest mitotic activity, as in mammalian

tissues, were most easily inhibited by the antagonists.

This effect was

completely prevented by folinic acid in a non-competitive manner.

Thy-
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midine gave protection at a later stage of de-velopment, but had no protective effect in the egg stage.

He felt that the drug concentration in

the cells was not enough to interfere with_ the de novo synthesis of RNA,
but that the tbymidine biosynthesis was sufficientJy inhibited to prevent
DNA synthesis and accounted for the tissue-specific nature of the observed
effects.
Delmonte and Jukes (1962) stated that during methotrexate therapy,
abnormal chromosomes and mitotic figures were seen which probab]y reflected
the drug's interference with intracellular nucleic acid synthesis and provided morphologic evidence of direct damage to the cells of the host.
However, they also stated that there was no morphologic evidence of direct
damage to the cell dissolution.
Risto.logic

chan~

This section is devoted to the review of microscopic tissue alterations that have been cited following methotrexate therapy in both clinical and experimental settings.
Skin:
Van Scott (1963) stated that in the normal process of mitotic
reduplication, a cell must double its DNA content during the intermitotic phase.

Since folic acid is essential for DNA synthesis, the effect

of methotrexate on the epithelium is to prevent or inhibit the cell from
reaching the state of mitotic preparedness.

This is recognizable by the

rate of mitotic figures observed in a section of tissue per unit time.
In integument, the process of mitosis is essential to replace those cells
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that exfoliate and are lost to the external environment.
In the normal epidermis, the rate of loss of desqua.mated cells is
such as to require a relatively low rate of mitosis in the single layer
of germinative cells or basal layer, and histologically, comparatively
few mitotic figures are found.
Rothberg et al (1961), using glycine

-c14

incorporation into the

normal stratum corneum as an indicator, found the turnover time of normal
epidermis to be approximate.ly 27 days.
Van Scott and Ekel (1963) observed an approximate ninefold increase
in the number of germinative cells in the basal cell layers, and a 27-fold

.

mitotic generation of epidermal cells in the hyperplastic epidermis of
psoriasis.

The skin of the upper back of six patients was chosen and,

for comparative study specimens, the inner aspect of the lower lip were
obtained in four of the six patients.

They had observed that it was un-

common for the oral mucosa to become involved with psoriasis, even though
it was continuous with epidermis.

They attributed this to the fact that

the population of germinative cells of the oral mucosa was normally large
or as they termed it "psoriasiform".
Mitoses were found to occur in the three lower most cell layers of
oral mucosa which, as in psoriatic epidermis, are often discernible by
their deeper stainability.

Another similarity of the oral mucosa to

psoriatic epidermis was that the germinative cell population per unit
surface of oral epithelium was augmented by undulations of the subrnucosal
connective tissue papillae.

However, the number of mitoses per unit sur-
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face area of mucosa, while it was more than three-fold than in uninvolved
epidermis, was still less than that in psoriasis.
Other similar characteristics shared by the oral mucosa and the
psoriatic skin were parakeratosis, absence of a granular layer, and permeability for topically applied substances, all of which seem to be correlated with incomplete keratinization secondary to a heightened turnover
time of the epithelium.
More recently, an autoradiographic study of the turnover times
of normal and psoriatic epidermis was done by Weinstein and Van Scott (1965)
using tritiated tbymidine injected subepidermally.

A total turnover time

of 26-27 days for normal epidermi&was found versus 4 days for that of
psoriatic epidermis.
Van Scott' (1963) felt that since the total thickness of the normal
epidermis is composed of maf.\Y cell layers, af.\Y interference with the mitotic replacement during an interval of one or a few days would interfere
very little with the protective function of this epithelium.

Therefore,

after moderately large doses of the f olic acid antagonists for a limited
period, grossly detectable skin changes would be minimal in nature.

Clini-

cal changes may occur in skin following large doses, but these did not
seem to result primarily from interference with mitotic replacement of
the epidermis.
A limited amount of investigation of methotrexate activity on normal epithelium has been performed, such as the study of Robinson et al

(1969).

However, the majority of studies on methotrexate action have
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been reported in treatment of psoriasis.

Here the turnover time was

found by Van Scott (1963) to be on1y three to four days.

Therefore, he

felt that psoriatic epidermis, because of its high turnover dynamics,
was well-suited for the investigation of methotrexate action; especial1y,
since this type of epidermis would be exquisitely responsive to the drug
activity.
The use of f olic acid antagonists in the treatment of psoriasis
was introduced by Gubner and August (1951); and the work of Rees and his
associates (1955, 1959) established that this treatment was effective and
relatively safe.
Van Scott and Reinertson (1~59) treated a total of eighteen
psoriatic patients, 30-76 years of age, with several different chemotherapeutic agents, both topical1y and systemically.
given methotrexate

Six of these were

0.5 mg-5 mg/kg in a single intravenous dose and the

epithelium was observed in conjunction with the following laboratory
tests:

white blood cell count, hemoglobin, platelet count and spermatozoa

counts (on 2 patients given aminopterin and in two patients given methotrexate).

All tests were repeated during and after therapy.

Scalp hair

roots were examined during therapy for arry presence of dysplasia.
The skin biopsies of the treated patients revealed not a single
cell in mitosis twenty-four hours after the initial injection of methotrexate.

Within forty-eight hours a few cells in mitosis were found.

Since keratohyaline granules could be identified in cells of the upper
malpighian layer and the formation of tonofibrils continued during therapy, 'they concluded that the cytoplasmic activity was undisturbed.

~

The various laboratory procedures disclosed a lowering of the white
blood cell count and platelets in the peripheral blood.

In addition,

nausea and/or ulceration of the oral mucous membrane occurred.

Dysplasia

of the roots of anagen, or growing hairs was observed, with or without
hair losses.
Failure of topical methotrexate, in this study, to affect psoriasis
locally, suggested to them that its pharmacologic action required initiation at a distant systemic site.
An interesting finding during their investigation was that spermatogenesis was depressed.

49%

The spermatozoa count depression ranged from

to 9Cf/o, and the total spermatozoa ~epression ranged between 6']5/o and
The sperm counts were done twelve to fourteen

d~s

97%.

after the single intra-

venous dose of methotrexate or oral arninopterin for several repeated
courses.

However, the depression was determined not to be permanent,

since the two patients who had taken arninopterin, revealed normal counts
two and three years later.
Biro et al (1967) in treating psoriatic patients noted that twentyfour hours following a single

50 mg. intra.muscular dose of methotrexate,

mitotic figures were no longer prominent with a marked decrease in the
mitotic index.

Pyknotic epidermal cells were found in large numbers in

the two or three cell layers adjacent to the basement membrane.

They

felt that the location and number of pyknotic cells were suggestive of
some relationship to the mitotic process.
dermis.

No change was seen in the

After 72 hours the mitotic index returned to pre-injection

levels or higher, and pyknotic cells were virtually absent.

Epidermal
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thickness and acanthosis were measured and no lasting change was produced.
Halperin and Ohkawara (1967) determined the effects of methotrexate on the enzymes of carbohydrate metabolism in psoriatic epithelium.
They treated five patients with intramuscular methotrexate once a week.
Many of the enzymes involved in carbohydrate metabolism were assayed
prior to the treatment and at various times during treatment.

They found

that most of the enzymes measured decreased after therapy and there were
no specific enzymes which were marked}.y resistant to methotrexate or
'
markedly sensitive to its action. Psoriatic skin and surrounding normal
appearance skin shared this suppression of enzyme activities.
involved areas, the extent of

cli~cal

In the

improvement corresponded in gene-

ral to the measurable decreases in enzyme activities.
From their results, they concluded that methotrexate depressed
enzyme activities in a rather nonspecific manner.

They felt that since

these enzymes are made by the same mechanism as any other cellular protein, the action of methotrexate would seem to depress protein production
in general within the cell.

They stated that protein formation was a

complex process that required activated amino acids, transfer ribonucleic
acids, ribosomal RNA, messenger RNA and DNA templates.

Also necessary were

an adequate supp]s" of the various enzymes for forming these molecules and
nucleotides in the form of adenosine or guanosine triphosphate as an
energy source.
Since it has been determined that methotrexate binds much more
strong]s" to the enzyme folic reductase than to folic acid itself, they
agreed that all these reactions which required tetrahydrof olic acid for
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their synthetic pathways would be affected.

However, they felt that the

decrease in enzyme levels noted in their treated patients were primarily
due to a lack of protein synthesis, secondarily to the effect on the DNA
and RNA synthesis.

Yet, they were unable to substantiate this hypothesis

with experimental proof.
Another observation of note in their project was an unexpected
drop in enzyme activities in the uninvolved epidermis of a magnitude comparable to that in the involved epidermis.

No gross changes were noted

in the uninvolved skin clinically.
Gordon et al (1967) treated patients with various agents for psoriasis, giving two of them 20 mg. methotrexate I.V. weekly and one patient
methotrexate

2.5 mg orally daily for seven days. Biopsies were taken

daily for one week, weekly for one month, and then monthly.
the back was stained with H and E.

Skin from

They classified the results according

to the effects noted on each layer of epidermis.

The parakeratosis of

the stratum corneum disappeared by the sixth day after injection of methotrexat e.
day, and a

The stratum granulosum assumed a normal appearance by the fifth

78%

decrease in the stratum malpighii occurred by day four, but

then began to increase again.
They suggested that methotrexate acted mainly through mitotic
inhibition of the epidermal cells, since there was relatively little
. change in the inflammatory cell infiltrate or in the blood vessels.
In addition to the histopathological results, they determined that
both the epidermal and dermal acid mucopolysaccharides remained consistent and did not show any changes.

Only a moderate to minimal reduction
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in the dehydrogenases activities were seen.
In the realm of animal experimentation, Robinson and Stoughton (1969)
studied the effect of methotrexate on cell division in the epidermis of
4 - 5 day old Sprague-Dawley rats using the mitoses per 1000 interfollicular
basal cells as an indicator.

A dose of 5 mg/kg was administered subcuta-

neously on the ventral surface, and animals were sacrificed at 1/2, 1, 2,
3, 4, 15 and 24 hours after injection.
They found an obvious difference in the mitotic activity two hours
after injection and this depression lasted up to and including the twentyfour hour group.

The "t" test was not significant at the 1/2 and one hour

times, but the differences were significant at 0.53 from the 2 hour interval and remained so thereafter.

There was no significant difference bet-

ween untreated, water or methotrexate treated groups on the mean percentage distribution of the phase of the mitotic cycle recorded.
In discussingtheir results, they stated that Fukayama (1961) reported
the minimum

c2

time to be about six hours.

Thus cells with a double comp-

lement of DNA should be available for mitosis throughout this period.
suggested that for some reason

c2

They

cells were unable to enter the mitotic

cycle in the presence of this dosage of methotrexate.

They proposed that

this might be due to the failure of continuous entry of more cells into

c2

from the "S" phase, or to some effect on the 1i ttle known processes

within G itself.
2
They further mentioned that Pelc (1968) maintained that metabolic DNA
may be formed in some organs after the "S" phase and before mitosis.
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However, there is no published information on the formation of metabolic
DNA in the epidermis of the young rat.
Other theories on the exact reason for the failure of the onset of
mitosis with methotrexate include that of Jacobson (1954) in which he felt
that a lack of high energy compounds such as adenosine and guanosine nucleotides could lead to a failure of DNA, RNA and protein synthesis, thereby secondarily leading to a failure of mitosis.
Galper and Darnell (1969) found that methotrexate inhibited the synthesis of formylmethionine S-RNA in the mitochondria of HeLa cells, which
are of mammalian origin.

This observation could give credence to the be-

lief that methotrexate has a direct.effect on the protein synthesis of cells
as well.
Fry and McMinn (1966) correlated the findings of methotrexate therapy on
both the skin and the intestine of psoriatic patients.

A dose of 0.5 mg/kg

methotrexate was administered intramuscularly once a week.

They used the

mitotic skin count and that of the intestinal crypt cells for comparison.
Ten of twelve patients showed varying degrees of clinical improvement within
six weeks.

Two of three patients showed a decrease in skin counts at three

hours, and 3 out of 6 by the 24 hour interval.

Microscopically, the in-

testinal specimens had normal appearing villi with two of four patients
eliciting a decreased count at twenty-four hours.
The presence of degenerate cells with pyknotic nuclei (not included
in the counts) was regarded by them as evidence of the toxic effect of
methotrexate on both epidermal and intestinal cells; this was especially
evident twenty-four hours after the first injection.
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A marked fall in mitotic index after methotrexate occurred in the intestine and the skin, but unlike the psoriatic epidermis, the count of the
intestinal epithelium returned to the preinjection level by the seventh day.
They claimed that this observation supported the theory that the

'~ealing''

action of methotrexate in psoriasis is primarily a direct one on the premitotic end mitotic cells of the epidermis.
Regarding the utilization of the autoradiographic technique for studying the intestine of humans, they felt that injections of thymidine in
suitable dosage form were impractical, aside from the fact of the ethical
problem involved in giving a radioactive isotope with a half-life of
twelve years to patients with a

no~-fatal

disease.

Intestine
The other suitable tissue in which some work has been done with methotrexate or tritiated thymidine, and which can be related to the oral mucosa, is the intestine.

Both animals and humans have been used for inves-

tigation.
Loehry and Creamer (1969) have investigated the three-dimensional
structure of the rat small intestinal mucosa,both in the normal state and
under increased and decreased mitotic conditions.

To observe the intestine

in a repressed turnover state, they used a single 7.5 mg I.M. dose of methotrexate and studied the effects daily for a period of seven days.

In

conjunction with mitotic counting, two rats on day five after methotrexate
and two normal controls were injected intraperiotoneally with 100 uc of
tritiated thymidine.

One methotrexate and one normal rat were sacrificed
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after eight hours and the other pair 24 hours after the injection.

Auto-

radiograms were prepared on sections of small intestinal mucosa.
The mitotic counts revealed a marked reduction on days one and two with
a few mitoses reappearing on day three.

By day four to six, a marked

increase had occurred, a rate greater than that of the normal.

Mitotic

activity returned to normal by the seventh day.
The tritiated thymidine was administered during the period of regeneration of the intestinal mucosa, day five, so that the eight hour finding
in the control showed labeling of the crypt cells, while the methotrexate
treated had occasional labeling at the base of the villi. By
four hours after

3

the twenty-

H-TDT, the control rats showed labeling approximately

one third of the way up the villi, whereas, in the methotrexate treated
animals the lower two-thirds were labeled.

The latter observation was

agreeable with the higher than normal mitotic rate found in the regenerating intestine.
The height of the labeled villous cell column at twenty-four hours was
a mean of 22 cells in the control rats compared with a mean of 41 cells
in the treated group.
groups.

A standard deviation of 4.3 was present in both

The difference between the two groups, according to their findings,

was highly significant (p

<o. 001).

Their investigation showed that a single dose of methotrexate produced
ci

period of diminished cell production for the first three days after injec-

tion, followed by a three day period of increased cell production as the
mucosa regenerated.

Tritiated thymidine was utilized for the "specific

documentation"of the regeneration period dynamics.
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In the past, Phillips et al (1949, 1950), using lethal doses of aminopterin produced gross cytoplasmic vacuolization of intestinal epithelium in
the rat, mouse and dog; the epithelial lining of the intestine became desquamated with quite extensive leukocytic infiltration of the lamina propria.
Dustin (1950) noted striking mitotic inhibition of the mouse crypt
epithelial cells associated with nuclear degeneration, within a few hours
after lethal doses of aminopterin.

A return of mitoses was evident in

sixty hours, and by ninety-six hours, mitoses appeared normal.
Vitale et al (1954) administered nonlethal doses of aminopterin to
rats and observed a reduction in the number of mitoses, degenerated mitotic figures, nuclear remnants, and ~isintegrated crypt cells within four
and one-half hours after injection.

Normal mitoses returned 48 hours

later.
Trier (1962) reported on the morphologic alteration in the human proximal small intestine induced by methotrexate therapy of 2-5 mg/kg I.V.
in fourteen patients without evidence of gastrrointestinal disorders. Within three hours after the injection of methotrexate, mitoses per 1000 cells
were greatly reduced compared to baseline levels.
mitoses were virtually absent.

By six to twelve hours,

With this marked inhibition, he noted the

appearance of discrete, spherical bodies within the cytoplasm of many crypt
cells~

These bodies ranged from a fraction of a micron to 4 or 5 u in

diameter and varied considerably in structure.

Most of these bodies con-

tained some material which stained intensely with the Feulgen technique,
indicating DNA probably of nuclear origin.

The intracytoplasmic bodies

were confined exclusively to the crypt region and were never seen in the
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villous epithelium.

Trier noted the identical bodies in the crypt cells

of a biopsy taken from a patient 20 hours after 100 r of abdominal
x-irradiation.
He stated that the mitotic inhibition persisted for approximately
48 hours, with an increased return of mitoses from 48 - 96 hours, at which
time they were again normal.
With light microscopy the architecture of the small intestine did not
appear to be altered by methotrexate, nor were cytologic changes noted
anywhere than in the crypt.

However, under the electron microscope Trier

(1916) observed striking dilatation of cisternae of the endoplasmic reticulum and Golgi material, swelling witij fragmentation of the micro-villi
of some mucosal cells, and moderate mitochondrial
eight to 48 hours after methotrexate.

fragmentati~n

occurring

Adjacent to such damaged cells, mor-

phologically normal appearing cells were seen, and at 96 hours, no structural alterations were seen.

He concluded that methotrexate in a dose

range of 1.5 to 5.0 mg/kg regularly produced extensive but reversible morphologic alterations of the human small intestinal mucosa, by the inhibitory effect on nucleoprotein synthesis.

Also, these changes correlated

temporally with the period of gastrointestinal toxicity.
Oral Mucosa
Shklar et al (1966) in their investigation of the effect of methotrexate on chemical carcinogenesis of the hamster buccal pouch, had a
group of control animals to which only methotrexate was given.

A dose of

0.5 - 0.568 mg/kg was injected subcutaneously three times weekly for a
period of twelve weeks.

They stated that this dosage represented the
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maximum tolerated dose for this type of animal for the length of their
study.

Higher rated dosages of methotrexate were found to result in the

deaths of a number of similar experimental animals in observations they carried out prior to this experiment.,
They concluded that methotrexate not only appeared to accelerate the
formation of tumors in the buccal pouch painted with carcinogenic chemical,
but acted to produce or develop a more highly anaplastic type of carcinoma.
The buccal pouches of the methotrexate control groups in their study
were found to be free of gross pathology.

However, microscopically, there

was some evidence of collagen degeneration in the lamina propria of the
pouch mucosa of the 12 week group uf animals,
Two years thereafter, Shklar (1968) gave 0.8 mg/kg of methotrexate to
20 hamsters six months of age, weighing 115-130 grams.

This dose was ad-

ministered subcutaneously three times weekly for four weeks,

Sections of

tongue, palate and gingivae were taken then stained with H and E.

He

found that, although there were no striking gross oral changes visible,
microscopic examination of the sections revealed a decrease in the width
of the stratum corneum and a notable degeneration of the collagen bundles
in the underlying lamina propria, an observation in his earlier project.
The collagen bundles were clumped and stained more deeply in comparison
with the control specimens.

He concluded that the administration of non-

lethal dosages of methotrexate resulted in collagen degeneration and
epithelial atrophy of the oral mucosa, thereby possibly explaining the
occurrence of oral lesions in patients on such therapy.

No mitotic counts

or other criteria were done in this study, nor has any been noted elsewhere
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in the literature on the effect of methotrexate on the oral mucosa.
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Drug Application
Farber et al (1948) were the first to report results of aminopterin
treatment on five children with acute leukemia.

Their study covered a

period from November, 1947, to April 15, 1948.

The original group con-

tained sixteen children, of which ten showed some transient clinical,
hematologic, and pathologic improvement.
spond.

The remaining six did not re-

Of the five on which they elaborated, one twelve-year old boy

developed a stomatitis which interferred with optimal use of the drug.
Another twelve-year old boy developed minor ulcerative lesions of the
oral mucosa, resulting in dose reduction.
Since this initial report,
investigated.

nu~erous

clinical applications have been

Bertino and Johns (1967) stated that among them are the

treatment of neoplastic diseases, which include choriocarcinoma, Burkitt's
lymphoma, palliation of patients with epidermoid carcinoma of the head
and neck and also of the lung.

They mentioned that the use of metho-

trexate in large intermittent doses has produced objective responses in
about 30 to 50 per cent of the patients treated for head and neck carcinoma.

However, these responses have been of short duration.

In addition to the above, methotrexate therapy has been utilized in
psoriasis (Van Scott, 1964), and more recently, for the suppression of
the immune response.
Friedman, Buckler and Baron (1961), using male guinea pigs, revealed
that methotrexate prevented the development of a delayed skin-hypersensitivity response to diphtheria toxoid when ovalbumin was given as a single
immunizing dose.
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Prichard and Hayes (1961) found that no animal receiving both
aminopterin and bacilli simultaneously developed hypersensitivity, but
that all controls reacted positively.
Tobin and Argano (1967) administered a dose of 4 mg./kg. i.p. to
young adult male mice.

In addition, a single dose of tanned sheep red

cells was given I.V. to the experimental group.

Control animals were

given antigen but were only injected with distilled water intraperitoneally.

Their results indicated that there was significant suppression

of antibody production in the treated mice when compared with the control animals.

One month later both groups received a second injection

of sheep red cells, but no additional methotrexate.

In this instance,

they found that the antibody titres were equal in both groups.

They

concluded that in this particular system, methotrexate did not induce
a permanent refractory state to the antigen, although it was capable of
suppressing the primary immune response.
failed to induce tolerance.

That is to say, methotrexate

From these findings they concluded that

methotrexate may have therapeutic implications in the treatment of autoimmune diseases in man.
Of particular note is the work of Broughton (1967) on homologous
tooth transplants.

He transplanted maxillary and mandibular tooth buds

from a 50-day fetal guinea pig into the subcutaneous space in the axillary region of adult guinea pigs.

This was according to the method of

Fleming and Soni (1965).
The experimental guinea pigs were injected with 5 mg. of metho-
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trexate i.p. one day prior to transplantation and daily thereafter for
three weeks.

Then the injections were given every other day until the

animals were sacrificed.
injections.

However, the control animals were not given

On the fifteenth postoperative day and for one month there-

after one guinea pig from each group was sacrificed weekly.
Histologic examination of the sections of recovered tooth germs
showed a significant difference between transplants of the two groups.
The treated group showed normal formation of predentin, dentin, and
enamel.

The inflammatory response was negligible and appeared to have

little or no effect on the formation of the teeth.

However, in the con-

trol group there was evidence of a.severe inflammatory response, resorption of the dentin, and irregular enamel formation.

Therefore, he con-

cluded that methotrexate had suppressed the inflammatory reaction in the
treated group.
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Toxicity in Humans and Animals
The folic acid antagonists primarily affect the more rapidly growing tissues.

Bertino and Johns (1967) stated that the therapeutic index

in humans is narrow and, in most instances, toxicity of a significant degree
may result even when the antimetabolite is utilized in therapeutic doses.
For example, the bone marrow may be depressed and clinical signs of weakness, infection and bleeding may be present.

Each of these is related

respectively to the anemia, granulocytopenia, and thrombocytopenia seen
with this depression.

Pharyngitis, as well as ulcerations of the oral

and intestinal mucosa may occur.
Delmonte and Jukes (1962) noted that buccal lesions could precede
or accompany other symptoms of intolerance.

These buccal lesions were

described as small, shallow, painful, white or yellow, red-edged lesions
on the lips, tongue, or other oral mucosa.

Progression to ulcerative

lesions followed if therapy was continued.
The gastrointestinal symptoms of methotrexate toxicity include
anorexia, abdominal cramps, nausea, and vomiting.

Diarrhea, when it

occurs, is generally a more severe manifestation of drug toxicity. Delmonte
and Jukes (1962) stated that this usually coincided with the development
of extensive areas of atrophic degeneration and denudation along the entirety of the lower gastrointestinal tract.

They also stated that if

drug therapy continued after these signs appeared, severe toxicity resulting in death could follow.
Several minor signs of toxicity with no ulterior sequelae detrimental
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to the patient

are also possible.

Among them are brownish skin pigmenta-

tion, erythematous or exfoliative dermatitis, especially on the hands and
feet, and weight loss.

Delmonte and Jukes (1962) felt that this weight

loss attributed by some to the drug therapy, was probably more a consequence of the tumor patient's cachexia and poor physical condition.
Van Scott (1957, 1959) stated that transitory alopecia may occur
with therapy, due to reversible atrophy of anagenetic hair bulbs.
One of the most interesting aspects of the antifolic compounds is
their cumulative effect.

Rall (1963) stated that while the Ln 50 of rats

given methotrexate in a single dose is about lOOmg./kg., the LD50 for a
period of fifteen days of

administr~tion

is only about 0.25mg./kg.--

almost a thirty-fold difference in total dose.
Philips et al (1950) concluded that on a dose/kg. weight basis,
methotrexate was tolerated much better in mice, and slightly better in
dogs, than either aminopterin or dichloromethotrexate--other members of
the folic acid antagonist family.
Sullivan (1961) postulated that drug toxicity occurred mainly because of tissue absorption and prolonged contact of the drug within the
tissue, and not as a result of drug concentration in the blood.
Freeman and Narrod (1961) found that following oral and intravenous
methotrexate, toxicity was related directly to the rate of drug absorption rather than to the rate of its excretion.

They felt that the rate

of excretion was wholly a consequence of the delayed drug absorption.
Burchenal (1951) demonstrated that the toxic effects of mcthotrexate
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overdosage were reversible.

He recommended that 3mg. to 12mg. of citro-

vorum factor, the most effective antidote, be given intramuscularly immediately or within four hours of the onset of toxic symptoms.

When this

technique is utilized, the therapeutic effect of the agent is also neutralized.
The effect of methotrexate on the normal mouse leukocytes has been
documented by

Burchen~l

et al (1950).

They used 20 gram young male mice

and administered 3.0 mg,/kg. of the drug intraperitoneally three times
a week for ten doses.

The mice were weighed weekly and the dosage ad-

justed on a weight basis.

Control leukocyte and differential counts

were done before treatment, and
ing mice.

re~eated

every four days on the surviv-

In order that the counts could be done on free-flowing blood,

the mice were warmed for ten minutes under an electric lamp.

Then, a

small cut was made in a tail vein with a razor blade and the studies
done on the blood obtained in that manner.

Blood smears were stained

with Wright's stain.
They revealed that methotrexate appeared to cause only a slight
leukopenia in normal mice, with no alteration of the differential count.
This slight leukopenia was replaced by normal leukocyte counts around
the nineteenth day.

These normal counts in the treated animals remained

relatively stable for the duration of the thirty day experimental period.
Van Scott et al (1964) have provided evidence that treatment of
psoriasis with methotrexate 50 mg. intravenously once a week was effective and would be less toxic than oral therapy of 2.5 mg. daily for six
days, the recommended dosage schedule.

They further stated that oral
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mucosal ulceration following administration of folic acid antagonists
seemed to be a direct result of mitotic inhibition where cells normally
desquamated were not replaced.
On the other hand, Ryan et al (1964) felt that with low dosage
schedules of methotrexate mouth ulceration was no more common or consistent than the appearance of mouth ulcers in patients not on folic
acid antagonists.

Once ulcers appeared they may have failed to heal

unless the folic acid antagonists were discontinued.

They proposed

further that until the cause of the increased turnover of epidermal
cells in psoriasis was determined, it could not be assumed that the
demands for folic acid were any greater for nucleic acid synthesis than
for some of the other enzyme reactions subserving dermal tissue function, and which could indirectly lead to the increase in mitosis.

The

as yet undetermined amount of folic acid required for the increased
vasomotor or neuronal activity was also believed to play a role in the
etiology of psoriasis.
Van Scott (1963) stated that the eruptions of an erythematous nature
that may occur during treatment of psoriasis with methotrexate probably were due to effects of the drug on the small blood vessels.
As far as the hematologic effect, Vogel (1961) used a dose range
of 0.2 to 2.25 mg./kg. of methotrexate in his investigation of several
. antineoplastic compounds in determining their tumor-marrow index.

He

defined the latter as that dose causing 50 per cent destruction of the
marrow divided by that dose causing 80 per cent suppression of tumor
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growth in the same animal.

He utilized the 6c3HED lymphosarcoma in

mice for his observations. His obtained value of 3.2 mg./kg. of methotrexate was the dose which would cause 50 per cent marrow destruction.
Sloboda (1960) compared the effect of several folic acid antagonists upon mice bearing the 6c3HED lymphosarcoma to establish a quantitative means of comparing these compounds.

He used the carcinostatic

index, which he described as the toxic dose/effective dose, to effectively and quickly summarize the attributes of a compound as to its
effect upon the tumor-bearing mice.

He found that a dose of 0.705 mg./

kg. of methotrexate produced an efficacy ratio (control/treated) of 2,
while 2.10 mg./kg. was the dose wh}ch produced a differential weight
change of 3.4 grams between the control and drug treated animals.

B. Autoradiography
The method of autoradiography has

be~n

described by Fitzgerald

(1953) as dependent upon the fact that radioactive isotopes may be
localized to a given area in a histologic section, as well as to individual cells.

The tissue under study is placedsubadjacent to a

photographic emulsion for an adequate time to allow exposure of the
emulsion.

The emulsion is then developed as in ordinary photography

and the processed emulsion is then referred to as an autoradiogram.
It consists of accumulations of silver granules which appear black
and which overlie the areas in the tissue containing the radioisotope.
The ionization of the silver bromide crystals contained in the photo-
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graphic emulsion is produced by the rapidly moving charged particles
emitted from the radioisotopes, thereby permitting the observation of
the presence of the radioisotope (Schoenheider, 1960).
Schoenheider (1960) stated that the chemical, as well as the biological behavior of a substance labeled with a radioisotope were identical
to that of its stable counterpart provided that the amount of

radioacti-

vity that was contained in it was small enough not to have a significant
radiochemical effect and that the amount of material injected was small
enough not to produce a significant increase in the amount of the substance
in circulation.

Thus, the labeled substance could be considered a true

"tracer" of normal in vivo metabolism.
Hughes et al (1958) stated that tadioactive tritium was an excellent substance to utilize for a label, since very high resolution could
be obtained; yet, it has very weak energy and a short range of beta rays.
In tissue the maximum distance a beta ray will travel is six microns,
and half of the particles will travel less than one micron.

Therefore,

the majority of the activated silver grains of an autoradiogram should
lie within one micron of their source in the tissue.
The use of tritium as a tracer substance in autoradiograms is a
useful adjunct in studying the presence of a chemical substance, such as
thymidine, or its metabolites in a histologic tissue section.
Lajtha, Phil, and Oliver (1959) concluded that thymidine was a
specific component of DNA, since it labeled only DNA. Tritium was
determined to have a half life of 12.26 years and a disintegration rate
of 0.0063 per day.
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Messier and Leblond (1960) stated that the synthesis of DNA is
known to occur before mitosis.

Therefore, if the radioactive precursor

were given at that time, the nucleus would become radioactive and, using
radioautography, could be noted even before mitosis occurs.

These nuclei

retained the label of radioactivity and passed it on to the daughter cells
during mitosis.

Therefore, tritiated thymidine is a valuable compound

for the detection of newly formed DNA by the method of autoradiography.
In their study they reported on the labeled nuclei in the mouse
tongue and epidermis after eight hours, twenty-four hours, and seventytwo hours from the initial tritiated thymidine injection.

They investiga-

ted the various rat tissues more extensively with additional detailed
time interval observations.

Since methotrexate is known to interfere

with DNA synthesis, the autoradiographic method is a most accurate one
for the determination of the specific effect of this drug on the oral mucosa.

CHAPTER III
MATERIALS AND METHODS
Fifty-two adult male mice, Swiss-Webster strain,weighing an average
of

25 grams, and on a diet of Purina Chow for mouse or rat, were used.

Food and water were given ad libitum. Blood for initial and final white
blood cell counts, and differential Wright's blood smears were obtained
by cutting off the tip of the tail of each mouse and aspirating blood into
1 cc. disposable syringe.

Weights were taken initially, periodically du-

ring the six-day injection period,.and at the time of sacrifice.

Metho-

trexate dosage was adjusted according to a weight basis.
The experimental mice, 26 in number, were injected intraperitoneally
with a therapeutic dose of 2.5 mg/kg of a 1.53 starch solution of Methotrexate Sodium (supplied by Lederle Laboratories, Adolph E. Sloboda, Ph.D.,
Pearl River, N.Y.) daily for a period of six days.

Twenty-six control

mice were injected intraperiotoneally with 0.4 cc. sterile water daily for
the same period.

Then, on the seventh day both groups were injected intra-

peritoneally with 50 uc. of tritiated thymidine (supplied by Schwarz Bioresearch, Orangeburg, N.Y.) and were sacrificed at intervals of 15, 30,

45 and 60 minutes, 2, 3, 4, S, 6, 7,8,9, 10, 12, 14, 16, 18, 20, 24, and
.48 hours following the injection.
The tongue and palate were dissected out on each mouse, fixed in formalin, dehydrated, and embedded in paraffin.
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Sections of the tongue and palate, cut at 5 microns were prepared.
slides from each sacrifice period were selected for autoradiography.

Three
Addi-

tional sections of each tissue from each time interval were stained by the
Hematoxylin and eosin method.
Autoradiographic Technique
The autoradiographic technique used was modified from that described
by Fitzgerald (1961).

Under darkroom conditions, a Wratten #2, Red Safe-

light 25 watt bulb was used.

A humidity of 703 and below was sustained.

The slides were dipped in Kodak NTB3 liquid emulsion (supplied by Eastman
Kodak, Rochester, N.Y.) and were air dried for 10 minutes.
placed in a black lightproof exposure box, section sides up.

Ten slides were
Lithium chlo-

ride was placed in the box for maitaining a low humidity, and black plastic tape was used to seal the box.
dity and temperature.

It was exposed for 10 days at low humi-

During the exposure time, the box must be maintained

in a position which keeps the sections upright.

After the 10 day period,

the slides were placed in a staining rack and developed for five minutes
at 60°F (18°c) in Kodak Dl9 developer.

The slides were rinsed in distilled

water for 30 seconds and then placed in acid fixer for 10 minutes.

Fol-

lowing this, the slides were rinsed in running tap water for 30 minutes.
Both the staining dish and slides were covered with tissue paper to prevent
dust from settling on them and allowed to dry in a stream of air.

The

processed autoradiograms were then stained with nuclear fast red and counterstained with indigo carmine.
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Cell Population
An area of 100 basal cells in length was determined and the corresponding numbers of total epithelial cells it represented was found.
then adjusted for a total population of 1000 epithelial cells.

This was
For each

time interval, 2-4 slides were utilized.
Percentile of Labeled Nuclei
Under high dry magnification 500 basal cell fields were counted.

The

number of labelled nuclei observed in an area of 1000 cells were recorded,
and from this, the mean and standard deviation were determined.
centages were converted to log

10

The per-

for the preparation of a curve (Figs. 4-5).

CHAPTER IV
FINDINGS
Within one hour after injection of tritiated thymidine, an average of
9.833 and 10.553 of the stratified squamous epitheUalcells in the tongue
and palate, respectively, were labeled in the control animals.

The expe-

rimental mice showed an average of 15.603 labeled nuclei in the tongue and
24.243 in the palate during the same interval.

(tables I,II)

The number of labeled nuclei in the tongue doubled from an average of
9.833 to 19.403 by the six hour period in the control animals.

The experi-

mental group showed a doubling of 15.603 to 32.753 in the number of epithelial cells in the tongue an hour later (7 hours).

(Table I)

In the palate of the control group the number of labeled nuclei doubled
from 10.553 to 27.503 by the sixth hour after injection of the tritiated
thymidine.

The experimental group showed doubling of labeled cells from

24.243 to 45.303 by the eight hour period.

(Table II)

The labeled cell values continued to climb and reached a peak of 73.803
and 67.303 in the control tongue and palate, respectively,during the 10-14
hour interval.
In the experimental animals the level of labeled cells reached a plateau around 273 in the tongue and 43% in the palate within the 10-14 hour
period.
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During the 12-24 hour interval the control group showed a gradual
decline in the number of labeled epithelial cells, while that of the
experimental group showed a recovery by maintaining an average of 253
labeled cells in the tongue and 343 in the palate.

(Fig. 4-5)

By the

end of 24 hours the total number of labeled nuclei in both control and
experimental groups were comparable.
The total white blood cell counts of the control group showed only
interpersonal variation and did not increase or decrease significantly
during the experimental period. (Table III)

On the other hand, the counts

of the treated group were found significantly to decrease 193 during the
six day treatment period.

(Table IV)

The differential white blood cell

count did not vary from the normal.
Upon comparison of the initial white blood cell counts of the control
and experimental animals a "t" value of 0.113 was obtained.
comparison of the initial and final control counts gave a
0.484.

(Table III)

A similar

'~"

value of

However, when the initial and final white blood cell

counts of the experimental animals were analyzed, a "t" value of 1. 783 at
50° levels of freedom was found to be significant (0.05

P

0.025).

(Table IV)
Throughout the six-day treatment period no significant weight loss
was noted.

(Table V)

CMTimV

DISCUSSION
Stratified squamous epithelial tissues from the tongue and palate of
the mouse have been investigated in regard to the specific effect of methotrexate upon these tissues.
During the first hour after injection of tritiated thymidine, the
control animals showed an average of 10% labeled epithelial nuclei versus
163 and 24% in the experimental animals.

This indicated that there was

initially a greater residue of inh}bited cells in the rnethotrexate treated
animals; that is, many cells in the experimental group were unable to proceed with DNA

synthesis and continue into mitosis, since they were thy-

rnidine deficient.

However, upon injection of the tritiated thymidine,

these inhibited cells did accept the thymidine, but still were unable to
proceed immediately into mitosis, as was evident by the delay in doubling
time of one hour in the tongue and two hours in the palate.
The actual time of doubling occurred between 6 - 14 hours in the control
group and 7 -14 hours in the experimental group.

This is evident since

the labeled cell values continued to climb, especially in the control group,
until a peak was reached during the 10 - 14 hour interval.

(Fig. 4-5)

However, at 10 hours only 233 of the experimental cells were labeled as
compared to 47% of the control group.
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This showed that the control animal
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cells were free to continue mitosis while the experimental cells were
suppressed.

Therefore, methotrexate at this therapeutic dosage was effect-

ive in inhibiting the epithelial cells since they were not labeled, and
a resultant delay into mitosis was observed.
The actual doubling time, as derived from the continued increase in
labeled values after 6 hours in the control group, agrees with the findings
of Schoenheider (1960) who reported a doubling time of eleven hours in the
stratified squamous epithelium of the ventral surface of the tongue in the
mouse.

Dhawan (1964) also found a peak of labeled epithelial cells in the

ventral surface of the tongue at 10 hours.
8 - 10 hours in the epithelium of

~he

He reported a doubling time of

palate in mice.

Joglekar (1964)

agreed with these findings in her study of the normal mouse interdental
papillae.
The delay in doubling time of one to two hours found in the tongue and
palate is supported by previous investigations of methotrexate inhibition
upon DNA synthesis and mitosis in the epidermis and intestinal mucosa of
both humans and animals.

Robinson and Stoughton (1969) observed depressed

mitotic activity in the epidermis within two hours after a dose of 5 mg/kg
of methotrexate in 4 - 5 day old rats.

Fry and McMinn (1966) noted a marked

decrease in the mitotic counts of the skin and intestine of psoriatic patients as early as three hours after methotrexate administration.

Trier

(1962) reported greatly reduced mitotic counts in human intestine within thre1
hours after drug injection.
The fact that the epithelial cells of the experimental animals in this
study elicited a recovery of mitotic activity during the 12 - 24 hour
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interval might be explained by Werkheiser (1963) who maintained that as
long as a sufficient level of methotrexate was present, all the available
folic reductase enzyme would be bound.

However, as time progressed, the

concentration of the drug diminishes and newly formed enzyme could be
utilized to continue DNA synthetic pathways.

The formation of new enzyme

can occur since it is essentially protein synthesis, which is not greatly
reduced by the presence of methotrexate.
During the six day treatment period no significant weight loss was
noted (Table 5).

This is in contrast to Sloboda (1960) who stated that 2.10

mg/kg of methotrexate for six days produced a differential weight change
of 3.4 gms between control and

tre~ted

animals.

However, his study also

involved the 6C3HED lymphosarcoma in the mice, and it may be assumed that
the weight change was due to influencing factors other than methotrexate,
as also stated by Delmonte and Jukes (1962).
The depression of the total white blood cell count by 193 found in this
investigation demonstrated that 2.5 mg/kg of

metho~rexate

is a therapeutic

dosage and is agreeable with the findings of Vogel (1961) who reported some
marrow destruction from a comparable dosage of methotrexate.
The fact that no significant change occurred in the differential count
of the experimental animals coincides with the results of Burchenal et al
(1950).

They concluded that with a 3.0 mg/kg dose of methotrexate given

three times a week to mice, no alteration in the differential count occurred.
The present investigation has shown that tritiated thymidine administration may serve as a model for studying the effect of a therapeutic dosage
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of rnethotrexate for a period of six days upon the tongue and palate of the
mouse.

CHAPTER VI

SUMMARY
Twenty-six adult male mice, Swiss-Webster strain, were maintained on
a therapeutic dose of methotrexate sodium, 2.5 mg/kg, daily for a period
of six days.

Twenty-six similar control mice were injected intraperito-

neally with 0.5 cc. sterile water for injection daily for the same period.
On the seventh day both groups were injected with 50 uc. of tritiated
thymidine and were sacrificed at

twenty intervals between fifteen minutes

and forty-eight hours.
The tongue and palate were sectioned at 5 microns, and the sections
were stained with hematoxylin and eosin.

Additional mounted sections also

were used to expose a coating of Kodak nuclear track emulsion NTB3 for ten
days, followed by development of the sections and staining with nuclear
fast red and counterstaining with indigo carmine.
The number of labeled nuclei in the basal and subsequent layers were
counted for each time interval.
At fifteen minutes labeled nuclei were observed in the epithelium of
the ventral surface of the tongue and of the palate in a random distribution.

Within one hour an average of 103 of the control group tongue and

palate were labeled as compared to 163 and 243 in the methotrexate treated
tongue and palate, respectively.

Through mitosis the cells had doubled
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in number within six hours in the control animal tongue and palate.

In the

experimental animals the doubling occurred at seven hours in the tongue and
eight hours in the palate.
The total white blood cell counts of the treated group decreased significantly by 193
Throughout the six day treatment period no significant weight loss was
noted.

CHAPTER VII
CONCLUSIONS
Ten per cent of the cells in the tongue and palate of the control animals were labeled within one hour.

In the experimental group an average

of 15.603 of the cells in the tongue and 24.243 of those in the palate were
labeled within the first hour after injection.
The basal cell population which had undergone DNA synthesis doubled in
number in six hours in the control tongue and palate.

Doubling in the

experimental tongue and palate occurred in seven and eight hours, respectively.
Methotrexate at a therapeutic dosage of 2.5
the epithelial cells in the mouse tongue and

mg/kg was shown to inhibit

palat~

since at 10 hours only

an average of 233 of the experimental cells were labeled as compared to
473 in the control group tissues.
The white blood cell differential count did not change significantly
in the experimental animals, while the total white blood cell count did
decrease by 193.
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APPENDIX
TABLE I
PERCENTILE OF LABELED CELLS IN STRATIFIED SQUAMOUS EPITHELIUM
OF THE VENTRAL SURFACE OF THE TONGUE IN ADULT MICE
Time
Interval
15
30
45
1
2
3
4
5
6
7
8
10

12
14
16
18
20
24

minutes
minutes
minutes
hour
hours
hours
hours
hours
hours
hours
hours
hours
hours
hours
hours
hours
hours
hours

Control
Percent

Log
Percent

12.35
8.10
11. 77
7.12
14.30
7.87
6.00

1.092
0.909
1.075
0.853
1.155
0.896
0.778

19.40
16.25
19.50
43.00
73.80
39.00

1.288
1.210
1.290
1.634
1.868
1.591

11.20
51.60

1.049
1. 713

Experimental
Eercent
13.25
17.15
14.75
17.25
14.37
17.00
16.25
5.40

1. 125
1.233
1.167
1.236
1.155
1.230
1.210
0.073

32.75
22.00
24.00

1. 515
1.342
1.380

27.50
16.25
30.50
2.00

1.439
1.212
1.484
0.031

Mean 22.75

Mean 18.03

Standard
Deviation 19.21

Standard
Deviation 16.73
"t" = 0. 692
O. 25>p>O· 20

62

Log
Percent
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TABLE II
PERCENTILE OF LABELED CELLS IN STRATIFIED SQUAMOUS EPITHELIUM
OF THE PALATE IN ADULT MICE
Time
Interval
15
30
45
1
2
3
4
5
6
7
8
10
12
14
16
18
20
24

minutes
minutes
minutes
hour
hours
hours
hours
hours
hours
hours
hours
hours
hours
hours
hours
hours
hours
hours

Control
Percent

Log
Percent

12.12
2.60
18.45
9.00
15.80
5.65
5.60

1.097
0.042
1.265
0.095
1.199
0.075
0.075

27.50
25.00
5.30
51.30
67.30
44.60

1.439
1.39!3
0.072
1.708
1.826
1.644

4.67
88.40

0.067
1.945

Experimental
Percent
28.30
18.95
5.30
25.48
26.98
14.14
9.30
14.60

1.447
1.277
0.074
1.407
1.430
1.155
0.097
1.165

28.60
45.30
21.67

1.447
1.653
1.322

43.30
22.00
36.00
6.00

1.637
1.342
1.556
0.078

Mean 25.56

Mean 23.06

Standard
Deviation 25, 16

Standard
Deviation 11. 87
"t II

= 0.335

0.35>p>O. 30

Log
Percent

64

TABLE III
TOTAL WHITE BIDOD CELL COUNI'S IN THE CONI'ROL MICE

Time Interval

Initial (C.)
cu/mm blooa

Final (Cf)
cu/mm blood

15 minutes

8,400

30 minutes

14,220
10,950
22,750
14,800
9,600
13,250
16,000
9,250
7,600
8,500
7,900
11,474
10,474
10,300
5,200
9,374
12,220
19,320
14,420
45,600
6,920
20,150
14,420
26,350

22,560
6,400
9,000
15,300
14,650
15,350
11,700
8,550
9,700
11,500
5,400
13, 150
12,400
19,850
5,800
14,250
12,500
36,750
8,450
9,600
13,200
19,200
15,300
19,850
10,550
15,000

Mean 13,796

Mean 13,306

9,256

45 minutes
1 hour
2 hours

3 hours

4 hours
5 hours
6 hours
7 hours
8 hours
10 hours
12 hours
14 hours
16 hours
18 hours
20 hours
24 hours
48 hours

Standard
Deviation f'/J78
Ci vs. Cf :

Standard
Deviation
11

t

11

= 0.0484

o.4875>P> o.475
11

t

11

= 0.113

qoso
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TABLE

"IV

TOTAL WHITE BI.DOD CELL COUNTS IN THE EXPERIMENTAL MICE

Time
Interval
15 minutes .
)0 minutes

45 minutes
1 hour
2 hours
3 hours
4 hours

5 hours
6 hours

7
8
10
12
14
16
18
20
24
48

hours
hours
hours
hours
hours
hours
hours
hours
hours
hours

Initial(Ei)
cu/mm blood

12,.500
19,2.50
21,000

11,450
19,300
8,900
22, 150
13,300
10,950
8,150
12,200
1r,200
6,000
7,150
27,850
11,750
14,500
17,850
7,450
11, 150
15,950
10,400
17,200

FinalCEr)
cu/mm blood
20,700
15,900
7,600
7,950
14, 750
7,700
9,050
8,500
10,050
19,800
24,600
10,450
9,700
2,350

7,550

9,850
9,850

14, 150
10,650
8,100
11,250
8,000
10,850
8,050
16,750
4,600
9,500
7,700

Mean 13,578

Mean 10,992

Standard
Deviation 5,245

Standard
Deviation 5,007

9,750

Ei vs. Ef :

"t'' = 1. 783

o.05>p>o.025
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TABLE V
WEIGHTS OF CONTROL AND EXPERIMENTAL ANIMAIS
Time Interval

Control
Initial
Final
Gms.
Gms.

15 minutes

23.0

30 minutes

27.3
22.1
24.5

25.6

45 minutes

3 hours

25.7

26.6
27.2
22.1
22.3

4 hours

5 hours

6
7
8
10
12
14
16
18
20
24

hours
hours
hours
hours
ho'urs
hours
hours
hours
hours
hours
48 hours

•

27.8
20.7
23.3

22.5

26.6
28.9

25.6

24.8
22.7
25.3
25.1
23.2
22.0
22.2
23.1
26.8
23.4
25.1
24.0

23.2
22.1
21.0
23.2
24.4
22.2
25.1
21.9

24.5
27.1
27.1
24.6
22.0

21.7
28.3
23.4
21.7
23.6
27.8
22.3
19.5
30.3
26.9
29.4
23.2
21.3
24.8
23.2
27.3
27.3
23.6
22.6

Mean 24.5

24.2

Mean 25.6

23.9

23.2
27.9
22.4
24.7
28.3

2 hours

27.7
23.5
23.9
24.4
27.0
28.3
24.9
21.9
29.3
24.5
24.o
23.2
25.8
27.7
21.6
31.7
26.6
28.6
28.7
22.7

27.5

25.6

22.5
1 hour

24.7
24.1
21.5
27.2
26.6
20.9
26.0
21.5
28.4
22.4

27.5

Experimental
Initial
Fina.l
Gms.
Gms.

Standard
Deviation 1.87

c vs.

26.5

25.0
25.5

2.26

25.8

Standard
Deviation 2.51

E fina.l weights :
0.40>p~O.J5

"t"

= 0.288

5.54
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a)

FOLIC ACID (PGA)

Pteroylglutamic Acid

b)

C'OON
I

0

••~

Mc-N-C--~~-CH 2
I H
"K
~ ..2.

CH1.
I

COOM

AMINOPTERIN (AMP)

4-aminopteroylgluta::nic Acid

o)

METHOTREXATE (MTX)

4-amino-N10_metbylpteroylglutamic Acid
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FIGURE 2

Folic Acid
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Enzyme
Complex
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Drug(Fol· R ctase
Enzyme
Complex

Single
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Acid

CF(citrovorum factor)
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) Vital
Patif.Way-s
Product

••Blockage by Methotrexate, Aminopterin
INHIBITION OF ENZYME FOLIC REDUCTASE
BY METHOTRElCATE, AMINOPTERIN ':'
*Adapted from:

Mandel (1959), p. 796.

69

FIGURE 3

Deo:xyuridylic Acid

Tbymidylic
Acid

DNA

Synthesis
--~·

cl

Division

5,10 Met lenetetrahyd.rofolic
Acid

olic
cia

Foli,eductase
~ Folic
Acid

• • - ..
; NADPH

(C1 unit)

•=Inhibition of Folic Reductase
by Methotrexate, Aminopterin
BIOSYNTHESIS OF THYMIDYLIC ACID:
Role of tetrahydrofolate coenzyrnes *
*Adapted from: Mead (1963), P• 937.
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Units, labels, and scales are identical to those used in Figure 4.
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